Karuna Therapeutics

KRTXNASDAQAcquired

Muscarinic receptor-based CNS therapeutics platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 177 days ago · archived: kept for reference, not maintained · where each field comes from

central nervous systempsychiatry

Pipeline at the time of the last update

DrugIndicationPhaseExpected data
KarXTschizophreniaNDA/BLA FiledNot disclosed▼
KarXTpsychosis in Alzheimer diseasePhase 3Not disclosed▼

Comparable companies

Bristol Myers SquibbAcadia PharmaceuticalsNeurocrine Biosciences
Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Karuna Therapeutics has 16 Phase 2 or 3 studies on ClinicalTrials.gov: 9 completed, 1 stopped early, 6 ongoing.

9

Completed

1

Stopped early

6

Ongoing

Stopped early

  • PENNANTPhase 3 · started 2022 · terminated

    Xanomeline and Trospium Chloride Capsules in schizophrenia · n=4

    Reason given: Company's business decision.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.